222 related articles for article (PubMed ID: 27185459)
21. Ultrasound Imaging of Muscle Contraction of the Tibialis Anterior in Patients with Facioscapulohumeral Dystrophy.
Gijsbertse K; Goselink R; Lassche S; Nillesen M; Sprengers A; Verdonschot N; van Alfen N; de Korte C
Ultrasound Med Biol; 2017 Nov; 43(11):2537-2545. PubMed ID: 28764967
[TBL] [Abstract][Full Text] [Related]
22. Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy.
Tasca G; Monforte M; Corbi M; Granata G; Lucchetti D; Sgambato A; Ricci E
Mol Neurobiol; 2018 Apr; 55(4):2959-2966. PubMed ID: 28456937
[TBL] [Abstract][Full Text] [Related]
23. Low D4Z4 copy number and gender difference in Korean patients with facioscapulohumeral muscular dystrophy type 1.
Park HJ; Hong JM; Lee JH; Lee HS; Shin HY; Kim SM; Ki CS; Lee JH; Choi YC
Neuromuscul Disord; 2015 Nov; 25(11):859-64. PubMed ID: 26319123
[TBL] [Abstract][Full Text] [Related]
24. Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.
Katz NK; Hogan J; Delbango R; Cernik C; Tawil R; Statland JM
Brain; 2021 Dec; 144(11):3451-3460. PubMed ID: 34542603
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic magnetic resonance imaging biomarkers for facioscapulohumeral muscular dystrophy identified by machine learning.
Monforte M; Bortolani S; Torchia E; Cristiano L; Laschena F; Tartaglione T; Ricci E; Tasca G
J Neurol; 2022 Apr; 269(4):2055-2063. PubMed ID: 34486074
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.
LoRusso S; Johnson NE; McDermott MP; Eichinger K; Butterfield RJ; Carraro E; Higgs K; Lewis L; Mul K; Sacconi S; Sansone VA; Shieh P; van Engelen B; Wagner K; Wang L; Statland JM; Tawil R;
BMC Neurol; 2019 Sep; 19(1):224. PubMed ID: 31506080
[TBL] [Abstract][Full Text] [Related]
27. Adding quantitative muscle MRI to the FSHD clinical trial toolbox.
Mul K; Vincenten SCC; Voermans NC; Lemmers RJLF; van der Vliet PJ; van der Maarel SM; Padberg GW; Horlings CGC; van Engelen BGM
Neurology; 2017 Nov; 89(20):2057-2065. PubMed ID: 29030457
[TBL] [Abstract][Full Text] [Related]
28. Exploring the influence of smoking and alcohol consumption on clinical severity in patients with facioscapulohumeral muscular dystrophy.
Vincenten SCC; Mul K; Schreuder THA; Voermans NC; Horlings CGC; van Engelen BGM
Neuromuscul Disord; 2021 Sep; 31(9):824-828. PubMed ID: 34407911
[TBL] [Abstract][Full Text] [Related]
29. Severe phenotype in infantile facioscapulohumeral muscular dystrophy.
Klinge L; Eagle M; Haggerty ID; Roberts CE; Straub V; Bushby KM
Neuromuscul Disord; 2006 Oct; 16(9-10):553-8. PubMed ID: 16934468
[TBL] [Abstract][Full Text] [Related]
30. Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.
Eichinger K; Heatwole C; Heininger S; Stinson N; Matichak Stock C; Grosmann C; Wagner KR; Tawil R; Statland JM;
Muscle Nerve; 2017 Mar; 55(3):333-337. PubMed ID: 27421252
[TBL] [Abstract][Full Text] [Related]
31. Multiplex Screen of Serum Biomarkers in Facioscapulohumeral Muscular Dystrophy.
Statland J; Donlin-Smith CM; Tapscott SJ; van der Maarel S; Tawil R
J Neuromuscul Dis; 2014; 1(2):181-190. PubMed ID: 25705588
[TBL] [Abstract][Full Text] [Related]
32. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy.
Osborne RJ; Welle S; Venance SL; Thornton CA; Tawil R
Neurology; 2007 Feb; 68(8):569-77. PubMed ID: 17151338
[TBL] [Abstract][Full Text] [Related]
33. Facioscapulohumeral muscular dystrophy. Phenotype-genotype correlation in patients with borderline D4Z4 repeat numbers.
Butz M; Koch MC; Müller-Felber W; Lemmers RJ; van der Maarel SM; Schreiber H
J Neurol; 2003 Aug; 250(8):932-7. PubMed ID: 12928911
[TBL] [Abstract][Full Text] [Related]
34. The FSHD muscle-blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy.
Banerji CRS; Greco A; Joosten LAB; van Engelen BGM; Zammit PS
Brain Commun; 2023; 5(5):fcad221. PubMed ID: 37731904
[TBL] [Abstract][Full Text] [Related]
35. Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.
Fitzgerald BP; Conn KM; Smith J; Walker A; Parkhill AL; Hilbert JE; Luebbe EA; Moxley RT
J Neurol; 2016 Dec; 263(12):2528-2537. PubMed ID: 27734165
[TBL] [Abstract][Full Text] [Related]
36. Quantitative muscle ultrasound versus quantitative magnetic resonance imaging in facioscapulohumeral dystrophy.
Janssen BH; Pillen S; Voet NB; Heerschap A; van Engelen BG; van Alfen N
Muscle Nerve; 2014 Dec; 50(6):968-75. PubMed ID: 24659533
[TBL] [Abstract][Full Text] [Related]
37. Multivoxel proton magnetic resonance spectroscopy in facioscapulohumeral muscular dystrophy.
Leung DG; Wang X; Barker PB; Carrino JA; Wagner KR
Muscle Nerve; 2018 Jun; 57(6):958-963. PubMed ID: 29266323
[TBL] [Abstract][Full Text] [Related]
38. Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy.
Lassche S; Voermans NC; Schreuder T; Heerschap A; Küsters B; Ottenheijm CA; Hopman MT; van Engelen BG
Muscle Nerve; 2021 Jan; 63(1):60-67. PubMed ID: 32959362
[TBL] [Abstract][Full Text] [Related]
39. Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study.
Chagarlamudi H; Corbett A; Stoll M; Bibat G; Grosmann C; Matichak Stock C; Stinson N; Shapiro J; Wagner KR
Muscle Nerve; 2017 Dec; 56(6):1108-1113. PubMed ID: 28214289
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients.
Signorelli M; Mason AG; Mul K; Evangelista T; Mei H; Voermans N; Tapscott SJ; Tsonaka R; van Engelen BGM; van der Maarel SM; Spitali P
Sci Rep; 2020 Oct; 10(1):17547. PubMed ID: 33067535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
